Articles related to BREAST CANCER

The video features an interview with Dr. Jason Mouabbi, a surgical oncologist, who discusses the management of invasive lobular carcinoma (ILC), a type of breast cancer that is less common than other types. He explains that ILC is more challenging to diagnose than other breast cancers because it does not form a lump, but rather spreads in a linear fashion throughout the breast tissue. Dr. Mouabbi highlights the importance of early detection and screening for ILC. He then discusses the treatment options for ILC, which may include surgery, radiation therapy, and hormone therapy. He emphasizes the need for personalized treatment plans for each patient based on their specific case and individual needs. Dr. Mouabbi also talks about the potential role of neoadjuvant therapy in improving outcomes for patients with ILC. Overall, the video provides valuable insights into the management of ILC and highlights the importance of early detection and personalized treatment plans.

Women who are overweight have an increased risk of developing breast cancer. It is unknown whether prior obesity still carries a higher baseline risk of breast cancer in women who have shed a significant amount of weight as compared to peers without obesity. Researchers assembled a retrospective matched cohort study of 69,260 women who were followed up for 5 years after bariatric surgery or the index date (1/1/2010 – 12/31/2016) to see whether there is a residual risk of breast cancer among patients who undergo bariatric surgery due to prior obesity. According to the findings, bariatric surgery was linked to a lower risk of breast cancer in women with prior obesity that was equivalent to a woman with a BMI under 25, as well as a lower risk when compared to all groups with a BMI of 25 or higher.

The 49-year-old breast cancer specialist typically sees patients two days per week and spends the rest of her time pursuing other interests such as research and public policy. Dr. Patt has testified before the Texas legislature and Congress on issues ranging from legislation aimed at reducing prior authorization hurdles to the need to reform the 340B Drug Pricing Program to ensure that more federal funds reach underserved populations in her role as executive vice president of policy and strategy at Texas Oncology, a large community-based practice with more than 500 physicians.

This study analyzed 147 patients with hormone receptor-positive and HER2-positive metastatic breast cancer (HR+/HER2+ MBC) who received first-line chemotherapy and dual anti-HER2 therapy using a real-world registry dataset. The efficacy of adding endocrine therapy to dual anti-HER2 therapy after chemotherapy discontinuation was studied retrospectively. The researchers discovered that endocrine therapy resulted in statistically significant and clinically meaningful improvements in both PFS and overall survival outcomes. In the first-line treatment of HR+/HER2+ MBC, the current standard practice is to administer a CLEOPATRA trial-based regimen that includes taxane, pertuzumab, and trastuzumab until the best response is achieved and then discontinue chemotherapy. These findings, with a hazard ratio of 0.52 for overall survival with the addition of endocrine therapy, confirm that all patients with HR+/HER2+ MBC should receive endocrine therapy after achieving the best response with chemotherapy.

The National Cancer Database analysis highlights the difficulty in identifying a single time point before which primary surgery should be completed in patients with breast cancer. There were two major findings: (1) 12% of patients who had surgery more than 8 weeks after diagnosis had significantly lower overall survival, and (2) patients with lower socioeconomic status had a longer time to surgery.

A look into the results of a few patients that took part in a phase 1/2 trial at the Icahn School of Medicine at Mount Sinai in New York City: a woman who had breast cancer for 23 years and gone through 12 lines of therapy and a man with non-Hodgkin lymphoma (NHL) since 2017. Both showed complete response to the novel vaccine.